Vericel Shares Fall 10% After 4Q Forecast Misses Estimates

Dow Jones

15 Jan

By Stephen Nakrosis

Shares of Vericel fell after the maker of advanced therapies for the sports medicine and severe burn care markets issued guidance that missed estimates.

The stock fell 10% to $52.50 in post-market trading on Tuesday. Shares ended the day's regular session down 1.5% at $58.76.

The Cambridge, Mass.-based company said it now expects fourth quarter revenue of $68.2 million to $68.7 million. That would miss the $77.9 million estimate of Wall Street analysts surveyed by FactSet. The company had guided for revenue of $76 million to $80 million

Vericel said it now expects revenue of $237 million to $237.5 million for 2024, falling short of the $239.8 million forecast of analysts, according to FactSet. In November the company estimated revenue for 2024 of $238 million to $242 million.

Write to Stephen Nakrosis at stephen.nakrosis@wsj.com

(END) Dow Jones Newswires

January 14, 2025 18:34 ET (23:34 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2503635253"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2503635253\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2503635253?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-01-15 07:34","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2503635253","market":"sg","top_or_hot":-1,"title":"Vericel Shares Fall 10% After 4Q Forecast Misses Estimates","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Stephen Nakrosis \n</p>\n<pre>\n \n</pre>\n<p>\n  Shares of Vericel fell after the maker of advanced therapies for the sports medicine and severe burn care markets issued guidance that missed estimates. \n</p>\n<p>\n  The stock fell 10% to $52.50 in post-market trading on Tuesday. Shares ended the day's regular session down 1.5% at $58.76. \n</p>\n<p>\n  The Cambridge, Mass.-based company said it now expects fourth quarter revenue of $68.2 million to $68.7 million. That would miss the $77.9 million estimate of Wall Street analysts surveyed by FactSet. The company had guided for revenue of $76 million to $80 million \n</p>\n<p>\n  Vericel said it now expects revenue of $237 million to $237.5 million for 2024, falling short of the $239.8 million forecast of analysts, according to FactSet. In November the company estimated revenue for 2024 of $238 million to $242 million. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Stephen Nakrosis at stephen.nakrosis@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  January 14, 2025 18:34 ET (23:34 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Vericel Shares Fall 10% After 4Q Forecast Misses Estimates</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVericel Shares Fall 10% After 4Q Forecast Misses Estimates\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-01-15 07:34</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Stephen Nakrosis \n</p>\n<pre>\n \n</pre>\n<p>\n  Shares of Vericel fell after the maker of advanced therapies for the sports medicine and severe burn care markets issued guidance that missed estimates. \n</p>\n<p>\n  The stock fell 10% to $52.50 in post-market trading on Tuesday. Shares ended the day's regular session down 1.5% at $58.76. \n</p>\n<p>\n  The Cambridge, Mass.-based company said it now expects fourth quarter revenue of $68.2 million to $68.7 million. That would miss the $77.9 million estimate of Wall Street analysts surveyed by FactSet. The company had guided for revenue of $76 million to $80 million \n</p>\n<p>\n  Vericel said it now expects revenue of $237 million to $237.5 million for 2024, falling short of the $239.8 million forecast of analysts, according to FactSet. In November the company estimated revenue for 2024 of $238 million to $242 million. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Stephen Nakrosis at stephen.nakrosis@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  January 14, 2025 18:34 ET (23:34 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2503635253","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2503635253","pubTimestamp":1736897640,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of Vericel fell after the maker of advanced therapies for the sports medicine and severe burn care markets issued guidance that missed estimates.The stock fell 10% to $52.50 in post-market trading on Tuesday. Shares ended the day's regular session down 1.5% at $58.76.The Cambridge, Mass.-based company said it now expects fourth quarter revenue of $68.2 million to $68.7 million. That would miss the $77.9 million estimate of Wall Street analysts surveyed by FactSet. The company had guided for revenue of $76 million to $80 million. Vericel said it now expects revenue of $237 million to $237.5 million for 2024, falling short of the $239.8 million forecast of analysts, according to FactSet. In November the company estimated revenue for 2024 of $238 million to $242 million.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","VCEL":"Vericel Corporation"},"translate_title":"第四季度预测未达预期，Vericel股价下跌10%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VCEL":1},"content_text":"By Stephen Nakrosis \n\n\n \n\n\n  Shares of Vericel fell after the maker of advanced therapies for the sports medicine and severe burn care markets issued guidance that missed estimates. \n\n\n  The stock fell 10% to $52.50 in post-market trading on Tuesday. Shares ended the day's regular session down 1.5% at $58.76. \n\n\n  The Cambridge, Mass.-based company said it now expects fourth quarter revenue of $68.2 million to $68.7 million. That would miss the $77.9 million estimate of Wall Street analysts surveyed by FactSet. The company had guided for revenue of $76 million to $80 million \n\n\n  Vericel said it now expects revenue of $237 million to $237.5 million for 2024, falling short of the $239.8 million forecast of analysts, according to FactSet. In November the company estimated revenue for 2024 of $238 million to $242 million. \n\n\n \n\n\n  Write to Stephen Nakrosis at stephen.nakrosis@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 14, 2025 18:34 ET (23:34 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"code":"91000000","status":"200"}}}